This post will summarize highlights from biopharma conference calls - including Novartis, Roche, Baxter, and Sanofi - that are relevant either to Momenta Pharma MNTA specifically, or to the biosimilars space in general.
|
0 Comments
BiotechDueDiligence and HSP90 Central will be covering the 2013 AACR Annual Meeting live from Washington DC. This post will focus on abstracts to be presented by Astex Pharmaceuticals ASTX (partnered pipeline - see Parts 1 and 3 for internal ASTX assets), ArQule Inc ARQL, and BioSante Pharma BPAX.
Full coverage: Introduction Preview Part 1 (SNTA, ASTX, NVS, INFI) Preview Part 2 Preview Part 3 (ARRY, ASTX) Astex Pharma ASTX has a number of pharmaceutical company partners developing drugs on their behalf. This post will assemble and summarize key updates from this quarter.
DACOGEN: notes from partner and competitor calls can be found in a separate post. Watch for a future post analyzing DACOGEN royalties going forward (Astex guided for a decrease to $55m in 2013 vs $70m in 2012). (continue reading for additional notes) 2012 continues to be an eventful year for Momenta Pharma and their generic drug programs for Lovenox, Copaxone, and undisclosed biosimilars or follow-on biologics (FOBs). Continue reading below for a round up of updates from MNTA's partners and competitors in the space.
ASCO: Momenta will present preclinical data for M402, their heparin-based drug that has just started a phase 1/2 trial in combination with gemcitabine for pancreatic cancer. Abstract will be out May 16th. m-Enoxaparin (generic LOVENOX): -no mention of the MNTA-BAX follow-on biologics (FOBs) / biosimilars collaboration on the Baxter quarterly conference call -no mention of the long lost Teva Pharma $TEVA generic lovenox program on their 1q-2012 conference call. -no discussion of enoxaparin on Novartis $NVS (Sandoz) 1q-2012 conference call. -Sanofi $SNY 1q-2012 conference call comments (sorry for poor transcript) from Seeking Alpha and Morningstar has not yet posted one): "On the right side of the chart Lovenox performance even more remarkable, I believe was in €400 million just during the first quarter, a growth of 12%. So it says outside the U.S. where the product more or less never has been patent protected and is undergoing direct competition from [inaudible] many years. I believe [inaudible] inside US Lovenox performed [inaudible] patients mainly but not only due to the fact that we have seen no additional entries of a generic product. But I think it’s fair to say that also we have extreme customer loyalty [inaudible] evidently helped by continued supply problems of our existing competitors." -Watson Pharma $WPI 1q-2012 conference call excerpts: "Could you just comment a little bit about generic LOVENOX? How's that product doing for you?" "I think it's going all right. We're getting much better supply now. We were building up supply in the beginning. I think where the issue is, just to remind you, we only have the retail part of the business versus the non-retail. There were challenges in the beginning to only sell to the retail because many of our customers supply both retail and non-retail, including the hospitals. I think we have sorted those technical issues out pretty well, and we have steadily getting more market share. I think the prices have gone a little bit lower than we expected. We clearly see that both Sandoz and Sanofi have reacted to the market. But overall, we are quite pleased with where we are with the LOVENOX product." |
Categories
All
Archives
January 2020
|
RSS Feed
